Project Grant R35GM160153
- This $412,632 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to advance the biocatalytic synthesis of complex medicinal small molecules. The award, with a performance period from August 1, 2025 to July 31, 2030, will fund the development of computer-aided synthesis planning (CASP) tools to generalize known enzymatic reactions and predict routes for producing...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $450,313 in funding to The Johns Hopkins University from June 1, 2025 to May 31, 2030. The project aims to elucidate the molecular mechanisms and protein dynamics that enable the engineering of nonribosomal peptide synthetases (NRPSs), multidomain enzymatic factories that produce complex natural products with...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), totals $249,000.00 and will be performed from September 1, 2025 to July 31, 2028. The award supports research at the University of Kansas Center for Research Inc. aimed at developing chemoenzymatic approaches for synthesizing biologically active small molecules. Key objectives include enabling the preparation of...
- This $457,088 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of imaging tools to improve the activity of endolysins, a promising alternative to traditional antibiotics for treating antibiotic-resistant bacterial infections. The key products and services to be delivered include: Synthesizing a panel of internally quenched substrates to assess the activity of...
- This federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research on the discovery and engineering of ribosomally synthesized and post-translationally modified peptides (RiPPs). The $558,651 award, with a performance period from August 1, 2025 to July 31, 2030, will fund research conducted by Vanderbilt University to leverage RiPP biosynthesis for various biomedical...
- This federal Project Grant award of $524,400.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The funding supports research at the Scripps Research Institute in La Jolla, CA to develop novel chemical transformations and catalysts that enable the efficient synthesis of structurally complex small molecules for drug discovery. The research aims to address challenges in organic synthesis by...
- This federal Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of new reagents and methods for synthesizing oligophosphate constructs - phosphorylated biomolecules that play essential roles in human physiology and health. The $444,262 award, effective June 1, 2025 through March 31, 2030, will enable the Massachusetts Institute of Technology (MIT) to: Develop...
- This federal Project Grant award of $118,559 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to investigate metalloenzyme-guided discovery of new ribosomally synthesized and post-translationally modified peptide (RiPP) natural products. The key objectives are to: Structurally and functionally characterize copper-bound oxazolin, a natural product from the pathogens Nontypeable Haemophilus...
- The federal Project Grant award of $420,066.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will fund research to systematically characterize how regulatory networks control secondary metabolism in microbes. The project aims to use genome-wide screens and multi-omics approaches to predict and access the unexplored biosynthetic potential of microbes, with the goal of accelerating the discovery,...
- This $575,000 federal Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program supports research at Emory University to develop new synthetic methods and enabling strategies for the production of Ribosomally Synthesized Post-Translationally Modified Peptides (RiPPs). The goal is to create a universal catalytic platform to enable the synthesis of diverse RiPP natural products, which have shown promise as drug candidates but face...
This federal Project Grant award, valued at $456,500.00 and provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is focused on decoding the biosynthetic logic of modular polyketide synthases (PKSs). PKSs are enzymatic assembly lines that produce complex small molecules with medicinal importance, such as antibiotics, anticancer agents, and lipid-lowering statins. The key objectives of this research project are to understand how modular biosynthetic pathways are encoded at the protein sequence level, which could enable engineering the biosynthesis of novel chemical structures. The project involves expressing and purifying fragments of the rifamycin synthase (RifS) PKS assembly line, reconstituting the formation of its natural diketide in vitro, and conducting preliminary structural analysis using cryo-electron microscopy. The results of this research have the potential to transform human medicine and unlock sustainable methods for chemical synthesis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $456.5k | 8/28/25 |